The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Do you see improved outcomes when adding magrolimab to azacitidine in MDS and AML treatment?

Jun 16, 2020

During the American Society of Clinical Oncology (ASCO) Annual Meeting, the AML Hub was delighted to speak to Naval Daver, MD Anderson Cancer Center, Houston, US. We asked: Do you see improved outcomes when adding magrolimab to azacitidine in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) treatment?

In this video, Naval Daver describes patient characteristics, the safety and efficacy results from an ongoing trial. He also explains the rationale behind focusing on patients with TP53 mutations and describes the encouraging survival rates, duration of response and remission.

Do you see improved outcomes when adding magrolimab to azacitidine in MDS and AML treatment?